Duke University Health System Launches OneDukeGen
In a new precision medicine study, genomic and health data will be collected to understand connections between genetics, health, and disease.
The Duke University Health System and School of Medicine, in partnership with nference, an AI-enabled software platform provider, are launching OneDukeGen. The aim of this precision medicine study is to advance healthcare by integrating comprehensive genomic data and health information toward understanding hereditary disease susceptibilities.
Led by principal investigator Svati Shah, MD, MHS, Associate Dean of Genomics, the study hopes to recruit over 100,000 consented Duke patients. The study is designed to ensure a diverse representation of populations, and was informed through input from community groups. The study will also offer return of genetic sequencing results from the research.
The collaborators stated in a release that Duke researchers and clinicians who will work in tandem to integrate research findings into patient care, and hopes to bridge the gap between scientific discovery and clinical practice.
Learn more about the OneDukeGen study and how Duke patients will be invited to participate.
Reference: “Duke University Health System Launches OneDukeGen, a New Precision Medicine Study,” August 15, 2023. Duke University School of Medicine.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Delays Review of BLA Submission for Moderna's Novel Respiratory Syncytial Virus Vaccine
May 10th 2024Administrative constraints cause FDA to push back its review of data from a pivotal Phase III trial (NCT05127434), which demonstrated favorable clinical safety and efficacy for mRNA-1345, an investigational vaccine found to reduce the incidence of RSV-associated lower respiratory tract disease.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
